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Declining cancer incidence and mortality rates in the United States (U.S.) have continued
through the first decade of the twenty-first century. Reductions in tobacco use, greater
uptake of prevention measures, adoption of early detection methods, and improved treat-
ments have resulted in improved outcomes for both men and women. However, Black
Americans continue to have the higher cancer mortality rates and shorter survival times.
This review discusses and compares the cancer mortality rates and mortality trends for
Blacks and Whites.The complex relationship between socioeconomic status and race and
its contribution to racial cancer disparities is discussed. Based on current trends and the
potential and limitations of the patient protection and affordable care act with its mandate to
reduce health care inequities, future trends, and challenges in cancer mortality disparities
in the U.S. are explored.
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INTRODUCTION
Cancer mortality rates in the United States (U.S.) began to decline
in the early 1990s, following favorable trends in cancer risk fac-
tor reduction, such as reduced tobacco smoking among adults,
more widespread cancer screening and testing, and improved can-
cer therapies (1). This decline has continued through the first
decade of the twenty-first century. However, Black-Americans
continue to have the highest cancer mortality and shortest sur-
vival time among racial or ethnic groups, with the exception
of American-Indian/Alaska-Natives. The significant Black–White
disparity highlights national trends and is the focus of this review.
Definition and measurement of health disparities itself has also
undergone a significant evolution over the past two decades. There
is substantial evidence regarding racial/ethnic and socioeconomic
disparities in health-related behaviors, health status, and health
outcomes. Any assessment of racial disparities is compounded by
the fact that negative socioeconomic factors disproportionately
impact Black-Americans. Although disparities exist throughout
the continuum of cancer epidemiology, from exposures through
outcomes, this review concentrates on cancer outcomes. Control-
ling for cancer stage, cancer diagnosis presents the opportunity
for a “level-playing field” from which subsequent cancer outcomes
across population groups may be compared. Medical care, specif-
ically appropriate cancer treatments, driven by cancer biology,
can yield improved outcomes for specific cancers among some
racial and ethnic groups. However, overall cancer deaths continue
to be significantly higher among Black-Americans than White-
Americans (2). This review focuses on lung, colorectal, female
breast, and prostate cancer – cancers with high incidence rates
(lung, colon/rectum, female breast, and prostate) and high mor-
tality rates (lung and colon/rectum) using data from the National
Cancer Institute’s Surveillance, Epidemiology, and End Results
(SEER) program, and on factors contributing to cancer disparities.
DEFINING A DISPARITY
Socioeconomic and racial/ethnic disparities in health have been
recognized and documented in U.S. and the United Kingdom for
decades. The landmark Whitehall Study in Britain, begun in 1967,
demonstrated an inverse relationship of social class and disease
mortality (3, 4). Similar reports emerged in the U.S., highlight-
ing differences in disease incidence, survival, and mortality rates
based on socioeconomic status and race/ethnicity. These health
disparities also exist for cancer (5, 6). Despite the consensus that
social disparities in cancer exist, there has not been consensus
on disparity definition and measurement, and whether disparities
should be measured at the individual or ecological level (7–10). In
fact, the U.S. has experienced an evolution in vocabulary to define
and describe health disparities (Table 1). Prior to 2005, the terms
health equity and health inequity were avoided in favor of health
disparity (11). More recent federal and international documents,
however, embrace these terms. Notably, Healthy People 2020 con-
tains health equity as one of its overarching goals (12). The World
Health Organization refers to a health disparity as “the unfair and
avoidable differences in health status seen within and between
countries.” (13) This concept is vitally important. Though the
term health disparities implies a sense of injustice, explicit inclu-
sion of the terms equity, inequity, and injustice, recognizes that
social injustice contributes to health disparities.
How society views race and ethnicity in this context is criti-
cal to the measurement and elimination of disparities. From the
perspective of health disparities, race is correctly viewed as a social
construct (14). Race is a “social classification, based on phenotype,
and is a marker for social factors, which influence health” (15),
primarily socioeconomic status. Though distinctions are made
between race and ethnicity, both are social constructs and, from
the perspective of health disparities, the terms overlap and can be
viewed in combination as race/ethnicity. The decision on which
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Table 1 | Defining a disparity.
Agency Term used Definition
U.S. Department Health and
Human Servicesa,b
Health disparities Healthy People 2010: differences in the incidence, prevalence, mortality and burden of
diseases, and other adverse health conditions that exist among specific population groups
in the United States
Health disparity Healthy People 2020: a particular type of health difference that is closely linked with social,
economic, and/or environmental disadvantage
Health equity Health People 2020: attainment of the highest level of health for all people. Achieving
health equity requires valuing everyone equally with focused and ongoing societal efforts
to address avoidable inequalities
U.S. Department of Health and
Human Services Agency for
Healthcare Research and Quality
(AHRQ)c
Health care disparities Differences or gaps in care experienced by one population compared with
another . . .within the scope of health care delivery, these disparities may be due to
differences in access to care, provider biases, poor provider-patient communication, poor
health literacy, or other factors
Institute of Medicine (IOM)d Disparities Racial or ethnic differences in the quality of health care that are not due to access-related
factors or clinical needs, preferences, and appropriateness of intervention
U.S. National Institutes of Health
National Cancer Institute (NCI)e
Cancer health disparities Differences in the incidence, prevalence, mortality, and burden of cancer and related
adverse health conditions that exist among specific population groups in the United States
World Health Organization
(WHO)f
Health inequities Avoidable inequalities in health between groups of people within countries and between
countries that arise from inequalities within and between societies
aU.S. Department of Health and Human Services (2000). Healthy People 2010: Understanding and Improving Health 2nd Ed. Washington, DC, USA: U.S. Government
Printing Office.
bU.S. Department of Health and Human Services (2014). Health People 2020: Title Washington, DC, USA: U.S. Government Printing Office. Accessed August 7, 2014
at: http:// www.healthypeople.gov/ 2020/ about/ disparitiesAbout.aspx.
cAgency for Healthcare Research and Quality, 2009 National Healthcare Disparities Report (Rockville, MD, USA: AHRQ 2009) Accessed August 14, 2014 at
http:// archive.ahrq.gov/ research/ findings/ nhqrdr/ nhdr09/ index.html.
dSmedley BD, Stith AY, Nelson, eds, UnequalTreatment: Confronting Racial and Ethnic Disparities in Health Care (Washington National Academies Press) (2003), p. 3–4.
eNational Cancer Institute Accessed August 27, 2014 http:// crchd.cancer.gov/ about/ defined.html.
fWorld Health Organization. Social determinants of health Accessed August 27, 2014 http:// www.who.int/ topics/ social_determinants/ en/ or http:// www.who.int/
social_determinants/ thecommission/ finalreport/ key_concepts/ en/ .
variables to include and adjust in statistical models to quantify
racial and ethnic health disparities impacts the resultant magni-
tude of the disparity. Variables such as level of education, income,
and even diet, which are closely linked to the environment and
social context in which individuals live, may contribute to dispari-
ties and may more correctly be excluded from the statistical model
lest they serve to minimize or hide a “true” disparity (15). Agree-
ment on whether or not to exclude variables, which are socially
determined from statistical modeling used to measure racial and
ethnic disparities would serve to generate results that are compa-
rable across studies and could result in a more accurate picture of
the magnitude of racial and ethnic disparities in the U.S. over time.
SES measures, such as level of education, income, and depri-
vation are not consistently collected in public health surveillance
systems. This inconsistency adds a further complexity to disparities
assessment. When data are available, these data are often subjec-
tive, provided by self-report, and subject to potential inaccuracies.
Where individual measures are lacking or as an alternate, eco-
logical SES measures have demonstrated value. Two basic issues
lie at the heart of ecological SES measures: which socioeconomic
measures to include and at what geographic level (10, 16–18).
Though ecological measures provide a level of socioeconomic con-
text, the utility of these variables are limited by ecological bias in
that measures at the group level may not reflect those at the indi-
vidual level. The Public Health Geocoding Project (8, 19) reports
that data collected for block groups and census tracts, with an aver-
age 1,000 and 4,000 inhabitants, respectively, detect SES gradients
whereas data for zip codes, with an average 30,000 inhabitants, fail
to detect these differences. Data measures on economic poverty
were strongest at detecting gradients, which were not observed
with ecological measures of education. Thus, block group or cen-
sus tract measures, such as percent of population below the poverty
level, may provide a consistent and measurable SES marker at the
smaller ecological levels (19).
Another contributor to SES-related disparities in cancer mor-
tality is residential segregation. In the U.S., residential segrega-
tion remains highest for Blacks, compared to other racial/ethnic
minorities (20). Residential segregation concentrates Blacks in
poorer quality, more economically deprived neighborhoods than
Whites (21–23). Additionally, residential segregation restricts
access to quality health care, fresh produce, recreational facili-
ties, and economic mobility (24–29), which may influence risk of
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cancer mortality. Studies have reported the impact of racial res-
idential segregation on cancer health care and cancer mortality
using Census tract data (30–33). In the U.S., lung cancer mortality
among Blacks is higher than among Whites, but is highest among
Blacks living in the most segregated neighborhoods (30). Blacks
residing in the neighborhoods, which were most racially segre-
gated have a 10% higher lung cancer mortality rate compared
with those who reside in the least segregated neighborhoods, a
disparity that persists after adjustment for socioeconomic status.
This association is strongly supported by the demonstration that
an incremental increase in racial segregation is associated with a
corresponding increase in lung cancer mortality among blacks.
Studies examining racial residential segregation and breast cancer
care (31–33) indicate significant disparities in breast cancer care by
race. Overall,Blacks are more likely to present with late stage cancer
diagnosis. Higher racial segregation is associated with lower mam-
mography access and late stage cancer diagnosis. Black residential
segregation is estimated to account for 8.9% of this difference in
health cancer care. Inclusion of measures of residential segregation
is an important and relevant variable in assessment of cancer dis-
parities. This review focuses on characteristics of socioeconomic
and structural (e.g., economic resources, societal attitudes) factors
that contribute to disparities in cancer outcomes by race/ethnicity.
METHODOLOGY
The literature search was completed using MEDLINE and Google
Scholar. Search terms included combinations of “cancer,”“dispar-
ities,” “race,” “ethnicity,” “socioeconomic,” and “mortality.” Ref-
erence lists of comprehensive review articles were examined for
relevant articles not available in MEDLINE and Google Scholar
searches. This review focuses on recent mortality trends, and the
literature search was generally limited to articles published in 2004
or later. Reported cancer incidence and mortality data for the years
2000 through 2010 were extracted from the SEER program of the
National Cancer Institute. The SEER program reports incidence,
prevalence, mortality, and survival data dating back to 1969 from
reporting states and municipalities for some catchment areas. Inci-
dence rates were based on data from the SEER 18 database for the
years 2000–2011 (34). Mortality rates were taken from the mortal-
ity – all COD SEER database for the years 1969–2010 (35). Cancer
mortality disparity ratios were calculated using percent differences
between Black and White mortality by site. These were graphed
to include trend lines based on 10-year changes in mortality. The
discussion in this review thus focuses on characteristics of socioe-
conomic and structural factors that contribute to the resulting
disparity ratios in cancer outcomes by race/ethnicity.
OVERALL CANCER MORTALITY
Between 2000 and 2010, overall cancer incidence was higher
among Black men compared to White men and higher among
White women compared to Black women (34). Cancer mortality
over the same time period was higher for both Black men and
women compared to White men and women (35). Between 2005
and 2009, the overall age-adjusted mortality among Black men
was 288.3/100,000 compared to 216.7/100,000 for White men.
Despite lower cancer incidence among White women,age-adjusted
mortality was higher among Black women compared to White
women (180.6/100,000 compared to 155.0/100,000) (35). These
contrasting statistics indicate that there are factors, which affect
the outcomes for Black and White Americans after a cancer has
been detected and diagnosed. This review focuses on potential
contributors to these differences, with emphasis on the four sites:
lung, colon/rectum, female breast, and prostate.
Fixed-interval trends between 2000 and 2009 show some
encouraging findings. For Black men, all-site incidence and mor-
tality are declining at a faster rate than among White males
(Figure 1A). Lung cancer incidence and mortality and prostate
cancer mortality were also declining faster among Black men.
For the same time period, all-site mortality declined faster among
Black women than among White women (Figure 1B). Lung cancer
incidence and mortality, as well as cervical cancer incidence and
mortality, declined faster among Black females. The rate of these
declines is of interest because, if sustained, these trends suggest that
racial disparities may continue to narrow and could potentially be
eliminated over time.
LUNG CANCER
Lung cancer is the leading cause of cancer mortality in the U.S. The
downwards trend in tobacco smoking among adults following the
first Surgeon General’s report on tobacco and health in 1960s has
had the greatest impact on overall cancer rates, particularly cancers
of the lung and bronchus (1). Reflecting patterns in cigarette smok-
ing, in which cessation has been more pronounced among men,
with the risk of lung cancer reducing approximately linearly until
around 20 years after cessation (1). Whites and Blacks have signif-
icantly higher smoking prevalence than other racial/ethnic groups
in the U.S. For example, the 16.2% smoking prevalence among
Hispanics is significantly lower than both Blacks and Whites, as is
lung cancer incidence and mortality (34–37).
Since the late 1970s, there has been a steep decrease in initiation
of cigarette smoking among Black men, resulting in a narrow-
ing gap in lung cancer incidence rates between White and Black
men under the age of 40 (38). Between 2005 and 2010, current
smoking prevalence for Black men over the age of 18 decreased
from 26.7 to 24.8%, a greater drop than for White men over the
same time period: a smaller decrease from 24.0 to 22.6% (36).
Despite the steady decline in new diagnoses, Black men continue
to have a higher lung cancer incidence than White men. White
women have consistently higher lung cancer incidence rates than
Black women, reflecting historical female racial smoking patterns
(35). Both squamous cell and small cell (SCLC) carcinomas are
strongly associated with cigarette smoking. The changing preva-
lence of histologic subtypes over time shows strong evidence of
this association between tobacco smoking and lung cancer. Since
1980s, the rates of squamous cell carcinoma have been decreasing,
paralleling the decline in smoking prevalence (39). The fraction of
lung cancers classified as small cell (SCLC), which are rare among
non-smokers, has also been decreasing (40). Between 1986 and
2002, the proportion of lung cancers classified as small cell has
decreased from 17.26 to 12.95% (41). As SCLC rates have declined,
the proportion of lung cancers that have a weaker association with
smoking (e.g., adenocarcinoma) has increased. Between 2004 and
2009, there were higher incidence rates of squamous cell carcinoma
and adenocarcinoma among Black men and higher rates of SCLC
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FIGURE 1 | (A) All-site cancer mortality among men. United States 2000–2010 and disparity ratio trend. (B) All-site cancer mortality among women, United
States 2000–2010 and disparity ratio trend.
among White men, suggesting a correlation between the greater
prevalence of smoking and smoking-related lung cancers among
Black men (39). For women, the histologic incidence rates are not
indicative of smoking patterns since this histologic transition is not
discernible for women over the same period of time as for men.
For the years 2000–2009, Black men had higher lung cancer
mortality compared to White men, but lung cancer mortality rates
declined faster in Black men (3.0%/year) and women (1.0%/year)
compared with White men (2.2%/year) and women (0.6%/year)
(2, 38). Declines among Black and White men were not as great
as the declines among Hispanic men (3.3%/year) (37). A mor-
bidity and mortality weekly report on current smoking among
adults reports higher prevalence among Black men compared to
White men and for White women compared to Black women in
surveys conducted in 2005 and 2010, suggesting future trends in
lung cancer incidence by race and gender (36).
Between 2000 and 2010, the ratio in lung cancer mortality by
race decreased from 33.82 to 22.87% higher among Black men, for
an annual disparity decline of 1.09% (Figure 2A). Over the same
time period, lung cancer mortality increased from 5.94 to 7.40%
higher among White women compared to Black women, for an
annual disparity increase of 0.15%/year (Figure 2B). These trends
are reflective of changes in smoking prevalence patterns.
Though the disparity in lung cancer death rates between Black
and White men has been substantially reduced from a 50%
difference in 1990–1992 to a 26% difference in 2005–2009, the
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FIGURE 2 | (A) Lung cancer mortality among men, United States 2000–2010 and disparity ratio trend. (B) Lung cancer mortality among women, United States
2000–2010 and disparity ratio trend.
5-year overall relative survival has remained lower in Blacks com-
pared to Whites (13 and 16%, respectively). Disparities in lung
cancer mortality can be explained by a number of factors. Blacks
are more likely to present at a more advanced stage than Whites
(60 vs. 55%) (2). Surgical resection, the most successful treatment,
is an option only for localized disease (42) and individuals pre-
senting with advanced disease, have fewer options for successful
medical intervention. Thus, Black patients are less likely to have
the option of surgical resection, which may contribute to the lower
5-year survival. Further, Blacks are less likely to have surgical resec-
tion even when they presenting with localized disease (42). There
are lower rates of recommendations for lung cancer surgery in
Blacks (67% for Blacks and 71.4% for Whites) and higher refusal
rates after surgery was recommended (3.4% for Blacks and 2.0%
for Whites) (43).
Survival rates post-treatment also demonstrate racial varia-
tions. After treatment for advanced non-small cell lung can-
cer, 1-year survival was 22% in Black patients and 30% in
White patients (44). This finding presents evidence that factors
beyond disease stage and access to care affecting lung cancer
outcomes. One hypothesized factor is routine access to can-
cer care before diagnosis, which, if not available, can result
in poorer overall patient health at diagnosis (44). In an equal
access health care system (the U.S. military health system), where
routine access to cancer care is comparable for Blacks and
Whites, lung cancer survival was the same for Black and White
patients (45).
Studies have shown an association between lower socioeco-
nomic status and higher risks for cancer, including lung cancer, and
a greater likelihood of presenting at a more advanced disease stage.
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This relation is indicative of a complex underlying relationship
between race/ethnicity, socioeconomic status,and lung cancer out-
comes. For example, Black-Americans are almost three times more
likely to live in poverty than Whites (35 vs. 13%) and poverty is
associated with increased incidence of lung cancer and the like-
lihood of presenting at a more advanced (non-localized) stage,
which is related to poorer prognosis and survival (10, 46). Adding
to the complexity, individuals with a lower SES, indicated by both
poverty status and education attainment, are also more likely to
be current cigarette smokers (36).
The strongest risk factor for lung cancer, cigarette smoking,
and the most important determinant of lung cancer mortal-
ity, advanced stage at diagnosis, are both more prevalent in
Black-Americans compared to White-Americans. These differ-
ences are related to the higher incidence and poorer survival
in Black men. Although the difference in cigarette smoking
between Black and White men is decreasing, other factors beyond
individual smoking behavior persist, contributing to the differ-
ences in lung cancer stage at diagnosis and outcomes between
Black and White men. These contributors include differential
access to care, more advanced disease at diagnosis, differences
in treatment recommendations, and higher rates of surgery
refusal. For women, the higher smoking prevalence among White
women contributes to higher lung cancer incidence compared to
Black women. The mortality disparity between Black and White
women with greater mortality rates among Black women likely
reflects the same societal differences contributing to the dispar-
ity seen in men. The continuing decline in tobacco use in the
U.S. will result in downward trends in lung cancer mortality
for both genders and the greater cessation rates among Black
men suggest that the racial disparity ratio will narrow further
and possibly disappear in men. Defining and addressing soci-
etal factors will be necessary to eliminate lung cancer survival
disparities.
FEMALE BREAST CANCER
In the U.S., breast cancer has the highest cancer rate of new cases
among women and is the second leading cause of cancer death
in women. Between 2000 and 2009, breast cancer incidence rates
increased slightly (0.7%/year) among Black women and decreased
(1.0%/year) among White women (47). Prior to 2002, hormone
replacement therapy (HRT) was routinely recommended for pre-
menopausal and postmenopausal women. Evidence from the
Women’s Health Initiative and other studies reported that HRT
use may actually increase risk of breast cancer, as well as heart dis-
ease and stroke (1, 48). In response to these reports, there has been
a steep decline in HRT use in the U.S., which has been followed by
a decrease in breast cancer incidence.
Although breast cancer mortality has decreased annually by an
average of 2%, primarily due to earlier diagnosis and improve-
ments in treatment (49), this decline has been slower in Black
women than in White women (47). Breast cancer mortality is
higher among Black (50–53), Hispanic (50–52), and Native Amer-
ican (51, 52, 54) women than among White women. For example,
between 2002 and 2008, the relative 5-year survival for incident
breast cancers was 78% among Black women and 90% among
White women (47). The gap in breast cancer mortality between
Black and White women is increasing and, between 2000 and
2010, the breast cancer mortality disparity ratio increased from
30.3 to 41.8% (Figure 3). In White women, 5% of breast can-
cers are detected at an advanced stage, compared to 8% of breast
cancers in Black women (47). The difference in breast cancer mor-
tality may be due to more advanced stage at diagnosis and poorer
stage-specific survival among Black women (47). The later stage
at diagnosis among black women has been attributed to lower
frequency of mammograms, greater intervals of time between
mammograms, and less consistent follow-up of suspicious mam-
mogram results (47). Even so, across all stages of diagnosis, Black
women have poorer survival than White women. A potential
FIGURE 3 | Breast cancer mortality among women, United States 2000–2010 and disparity ratio trend.
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explanation is disparate access to high-quality treatment for Black
women (47). Additionally, Black women are more likely to have
longer delay from diagnosis until treatment (55), are less likely to
complete treatment appropriate for the tumor characteristics (56),
and are more likely to refuse treatment (57), compared to White
women.
The observed difference in breast cancer mortality between
Black and White women may also be influenced by more aggres-
sive tumor characteristics in Black women (58). Breast cancers
are often classified by at least three immunohistochemical mark-
ers – estrogen receptor (ER), progesterone receptor (PR), human
epidermal growth factor receptor (HER2). Hormone-negative
tumors have been associated with poorer survival (59–62), which
may be due to the lack of successful therapies for ER-negative
tumors (63, 64). Hormone-negative tumors are more prevalent in
Black (52, 60, 62, 65) and Hispanic (52, 62, 66–68) women, com-
pared to White women. In a study of women with tumors that are
negative for ER, PR, and HER2, Black women experienced double
the risk of mortality compared to White women (60).
Socioeconomic status also correlates with disparities in breast
cancer mortality. For breast cancer, like many other cancers, living
in a geographic area with high poverty and/or low educational
attainment is associated with poorer outcomes (54). The associa-
tion between low area SES and poorer survival has been observed
for Black (69), Hispanic (61, 69), Asian (69), and White (70)
breast cancer patients. Low area-level SES is also associated with
hormone-negative breast cancer in Black, Hispanic, Asian/Pacific
Islander, and White women (62, 71), which may influence dis-
parities in mortality. Individual-level SES factors are inversely
associated with mortality in breast cancer patients (72, 73). Among
a cohort of White breast cancer survivors, low educational attain-
ment was associated with 30% risk of breast cancer mortality (70).
Adjustment for socioeconomic status accounts for much of the dif-
ferences in survival for Black (74, 75) and Hispanic (66) women
compared to White women. Potential mechanisms for the relation
of low SES to breast cancer mortality include later stage at diagno-
sis (76, 77), increased risk of hormone-negative breast cancer (78,
79), and less frequent completion of high-quality treatment (1).
The interplay between socioeconomic status and race/ethnicity
contributes to breast cancer disparities. Differences in utiliza-
tion of early detection and treatment methods, access to quality
care, and tumor characteristics contribute to the racial/ethnic and
socioeconomic disparities in breast cancer mortality. Although
incidence of breast cancer is decreasing in the U.S., this dispar-
ity in mortality may continue unless there is a concerted effort
to introduce public policy initiatives to address broader societal
inequities, which are linked to both cancer and broader health
outcomes.
PROSTATE CANCER
The prostate is the leading site for new cancer diagnoses and sec-
ond leading cause of death from cancer among Black, White, and
Hispanic men in the U.S. (1). Improvements in anti-androgen
treatments and changes in the assignment of cause of death have
resulted in a decrease in reported prostate cancers since 1990 (1).
The only well-established risk factors for prostate cancer are age,
race, and family history of the disease, with African-American men
and Jamaican men of African descent having the highest prostate
cancer incidence worldwide (2). The prostate cancer prevention
trial showed evidence that anti-androgen therapies, specifically
with finasteride, can reduce prostate cancer risk among men over
the age of 55 (80).
In addition to significantly higher incidence of prostate cancers
when compared to White and Hispanic men, Black men have the
highest overall and stage-specific mortality rates (2, 81, 82). The
mortality rate is almost 2.5 times higher in Black men than in
White men (2). Compared to Hispanic men, the difference is even
greater (37). Between 2000 and 2009, the mortality rate due to
prostate cancer decreased faster among Black men compared with
White men (3.7 vs. 3.4%/year), which was only slightly lower than
Hispanic men (3.8%/year) (2, 37). Though Hispanics continue to
have lower mortality than non-Hispanic Blacks and Whites, the
steeper decline among Black men compared to White men pro-
vides evidence that disparity between the two groups is closing (2).
From 2000 to 2010, the prostate cancer disparity ratio decreased
from 147.84 to 139.80% higher among Black men, corresponding
to a decrease of 0.80%/year in the difference between Black and
White men (Figure 4). Some of the decrease in prostate cancer
mortality may be attributable to improved surgical and radiologic
treatment, dissemination of hormonal therapy for patients with
advanced-stage disease, and early detection by prostate-specific
antigen (2).
Although prognosis is generally favorable for all populations,
including high 5-year survival for Black, White, and Hispanic men,
studies have shown differences in treatment patterns by race,which
may contribute to the higher mortality in Blacks. Data from the
Cancer of the Prostate Strategic Urologic Research Endeavor Study
found that Black men were less likely to receive surgery compared
with White men with similar disease characteristics (83). Race
was correlated with type of treatment, with Black men being less
likely to have radical prostatectomy than radiation therapy or anti-
androgen therapy (83). Radical prostatectomy has been associated
with greater survival than other treatments, including radiation
therapy and watchful waiting (84, 85). Black men are more likely
to present with advanced disease, are administered different treat-
ment regimens, have shorter progression-free survival following
treatment, and have more treatment-related side effects compared
to White men (86).
Like with many other cancers, socioeconomic disparities
explain some of the differences in prostate cancer between races
(82). Results from a large prospective study suggested an increased
risk of advanced prostate cancer for a number of SES indicators,
such as neighborhood deprivation (87). For high-risk prostate
cancer patients, the number of bone scans, the likelihood of intent-
to-treat, and the likelihood of undergoing radical prostatectomy
were all greater for high SES men (88). Furthermore, overall mor-
tality and prostate cancer-specific mortality was lower for “white
collar” (high SES) men (88). These results show evidence of the
underlying relationship between SES, race, and prostate cancer
prognosis, since Black men are more likely to be in low SES groups.
Socioeconomic factors were found to explain 15% of the dif-
ference in tumor characteristics between Black and White men,
while the choice of treatment and physician explained another
17% (82). In one study, approximately 25% of the racial gap in
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FIGURE 4 | Prostate cancer mortality among men, United States 2000–2010 and disparity ratio trend.
mortality could be explained by racial differences in incidence and
treatment (82).
As a result of effective early detection and treatment options, the
mortality rates for prostate cancer will continue to decline for all
groups. Increased access to high-quality treatment has resulted in
steeper declines for Black men. Socioeconomic factors can explain
some of the differences in mortality by race and may eventually
lead to an elimination of prostate cancer mortality differences
by race.
COLORECTAL CANCER
Colorectal cancer is the second most commonly diagnosed cancer
in the U.S. and the second leading cause of death from cancer for
both sexes combined (1, 2). Incidence has been declining since
1985 (1). This decline may be associated with downward trend in
cigarette smoking and increasing non-steroidal anti-inflammatory
(NSAID) use (1). Further, colorectal cancer screening with either
sigmoidoscopy or colonoscopy has been increasing since the
1990s (1).
Incidence rates for colorectal cancer are higher among Black
men and women compared to White men and women (22 and
23% higher, respectively) (2). Colorectal cancer incidence is sig-
nificantly lower among Hispanic men and women than among
non-Hispanic Whites and Blacks (37). There are also racial dif-
ferences in colorectal cancer risk by site, which may produce a
difference in stage at presentation (89). Blacks are more likely
to develop cancer in the colon, while Whites are more likely
to develop cancer in the rectum, which is lower in the bowel
and more easily detected by screening (90). Identification of pre-
cancerous lesions is more difficult for cancers of the colon (90). As
a result, Blacks are at increased risk of developing advanced col-
orectal cancer compared with Whites, and Black seniors are more
likely to be diagnosed with late stage disease compared to White
seniors (90, 91).
Mortality rates are also significantly lower among Hispanic men
and women compared to both Blacks and Whites (37). Mortal-
ity from colorectal cancer declined between 2000 and 2010, but
the rate remains significantly higher among Blacks (34, 89, 92).
Over the same time period, the disparity ratio for colorectal cancer
mortality increased from 42.86 to 51.93% higher for Black men
compared to White men (Figure 5A) and decreased from 40.59
to 39.68% higher for Black women compared to White women
(Figure 5B). The average annual change was 0.91%/year for men
and −0.09% for women. Although mortality rates are declining
among both Blacks and Whites, the disparity between the two
populations is not closing, and, for men, may actually be widening.
A number of factors may contribute to the disparity in col-
orectal cancer mortality by race, including SES, stage at diagnosis,
treatment type, and physician and hospital factors (93). In a study
using a micro-simulation model, 19% of the disparity in colorectal
cancer mortality between Blacks and Whites could be explained
by differences in screening rates and 36% of the disparity could be
attributed to differences in stage-specific survival (94). In analy-
sis of data on a large cohort of Medicare beneficiaries diagnosed
with CRC, racial disparities decreased significantly after adjust-
ment for tumor characteristics, treatment, comorbidities, hospital
characteristics, and SES (93).
The relationship between race/ethnicity, SES, and their com-
bined effect on colorectal cancer outcomes reflect the same com-
plex relationship seen in other cancers. Comparing patients at the
same stage receiving the same treatment, survival rates are more
similar by race (95). A large meta-analysis showed that racial dis-
parities in survival for colon cancer are only slightly higher in
Blacks after adjusting for treatment and socioeconomic factors
(96). One study found that, after adjusting for socioeconomic
status, mortality in stage II and III colon cancer patients was
only marginally higher among Blacks than among Whites, with
a hazard ratio of 1.16 (95% CI, 1.01–1.33) (97). In another study,
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FIGURE 5 | (A) Colorectal cancer mortality among men, United States 2000–2010 and disparity ratio trend. (B) Colorectal cancer mortality among women,
United States 2000–2010 and disparity ratio trend.
socioeconomic status accounted for half of the disparity in stage III
of colon cancer mortality and half of the disparity in stages II and
III of rectal cancer mortality (98). Together, these studies suggest
that disparities in colorectal cancer mortality between Blacks and
Whites can largely be accounted for by differences in treatment,
hospital characteristics, socioeconomic status, and comorbidities.
The overall incidence and mortality rates of colorectal cancer
have been declining since 1980s, a change that is likely attribut-
able to reduced smoking, increased NSAID use, and widespread
screening. However, Black men and women continue to have the
poorest outcomes and this difference is associated with a number
of societal factors. The mortality disparity may increase in coming
years if SES-associated factors for Black-Americans worsen relative
to White-Americans.
DISCUSSION
In the U.S., over the period 2000–2010, there was an observed
decline in the cancer mortality rate by gender and race (Tables 2
and 3). Explanations for this improvement include decreased
smoking prevalence rates, improved and increased use of cancer
screenings, and more effective cancer treatments. Despite signifi-
cant gains in overall cancer mortality over this time period, per-
sistent cancer mortality disparities by race exist (Tables 2 and 3).
Although a greater decline of all-site cancer mortality among Black
men and women compared with their White counterparts has been
observed, significant age-adjusted cancer mortality disparities by
race persist. Black men and women have higher age-adjusted mor-
tality rates across the four common cancer types reported in this
review, with the exception of higher lung cancer mortality among
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Table 2 | Male cancer mortality rates and racial disparity ratios, United
States, 2000, 2005, and 2010.
Cancer site Year Black males
deaths per
100,000
White males
deaths per
100,000
Disparity
ratio (%)
All-sites 2000 341.2 243.4 40.20
2005 300.3 224.9 33.50
2010 264.4 207.1 27.70
Lung 2000 100.9 75.4 33.80
2005 87.0 69.1 25.90
2010 73.6 59.9 22.90
Prostate 2000 68.9 27.8 147.80
2005 57.0 23.3 144.60
2010 48.2 20.1 139.80
Colon/rectum 2000 35.0 24.5 42.90
2005 30.9 20.6 50.00
2010 27.5 18.1 51.90
Table 3 | Female cancer mortality rates and racial disparity ratios,
United States, 2000, 2005, and 2010.
Cancer site Year Black females
deaths per
100,000
White females
deaths per
100,000
Disparity
ratio (%)
All-sites 2000 193.2 166.0 16.40
2005 180.9 156.0 16.00
2010 166.3 145.9 14.00
Lung 2000 39.6 42.1 6.30
2005 40.1 41.7 4.00
2010 36.3 39.2 8.00
Breast 2000 34.4 26.2 31.30
2005 32.8 23.5 39.60
2010 30.2 21.3 41.80
Colon/rectum 2000 23.9 17.0 40.60
2005 21.4 14.3 49.70
2010 17.6 12.6 39.70
White women than among Black women. Later stage at diag-
nosis and less compliance or acceptance of proffered treatment
options suggested explanations for the disparities. However, why
Black patients seek treatment at later stages of illness or respond
differently to treatment options merits further exploration. As
cancer screening rates converge, it is important to examine why
racially patterned cancer survival disparities persist. An increas-
ing body of evidence points to underlying societal inequities as a
significant player in cancer outcomes disparities. How we resolve
to address the underlying identified societal inequities is critical
toward eliminating disparities in cancer outcomes.
RACE, ETHNICITY, AND SOCIOECONOMIC STATUS
A variety of data sources confirm that there are differences in can-
cer outcomes by race. Establishing how much of the difference in
cancer outcomes is the result of societal inequities and constitutes
a disparity is more nuanced. When assessing health disparities, a
crucial issue lies in determining when a difference is defined as
a disparity. The measurement of a disparity is complex because
a disparity is not measured directly, but is rather the difference
that remains after other variables have been accounted for in an
analysis. The decision regarding which variables are included in an
analysis will determine the magnitude, accuracy, and consistency
of reported disparities across studies. Whether to adjust for income
and education level, which impact health outcomes, or to consider
these variables primarily the result of societal inequities and on the
pathway toward health disparities, is critical to this debate. This
discussion has implications for tracking disparities over time and
for policy strategies to address disparities. For example, when edu-
cational attainment, a reflection of educational opportunity and
quality, is viewed as a pathway variable toward health disparities,
then education policy becomes a strategy to address health dis-
parities. Policy solutions that address access to and quality of the
health care system,discussed below,are certainly important toward
narrowing disparities, but cannot fully redress broader societal
inequities at the core of racial and ethnic health disparities.
PATIENT PROTECTION AND AFFORDABLE CARE ACT
The U.S. has long been criticized for failing to provide univer-
sal health care access to its residents. The patient protection and
affordable care act (ACA), signed into law in 2010, is designed
to increase access to health insurance and high-quality care for
all legal U.S. residents. Implementation of ACA will lead to a
projected decrease of 12 million uninsured in 2014 and 26 mil-
lion by 2017, as well as expanded health care access for millions
more Americans (99). Through provision of greater access, the
ACA should increase availability and utilization of preventive and
treatment services, with the goal of improved health outcomes
and reduced health disparities, which disproportionately impact
minority populations. A number of provisions of the law address
cancer-related care, including essential health benefits. The law
requires all health plans to cover preventive services that receive
an “A” or a “B” rating from the United States Preventive Services
Task Force with no cost-sharing (100). Services covered include
BRCA genetic counseling for high-risk patients, mammography,
Pap smears, three types of colorectal cancer screening, and tobacco
cessation interventions. The ACA also mandated the creation of
the Patient-Centered Outcomes Research Institute (PCORI) to
“. . . help people make informed healthcare decisions, and improve
healthcare delivery and outcomes, by producing and promot-
ing high integrity, evidence-based information that comes from
research guided by patients, caregivers and the broader healthcare
community” (101). Created in April 2013, the PCORI Advisory
Panel on Addressing Disparities awarded a total of $52.8 mil-
lion for 31 research projects – about two-thirds of which address
chronic conditions, including cancer (102). While it is premature
to discern the impact of ACA on overall cancer disparities, there
are some early indicators of its potential.
Human papilloma virus (HPV) vaccines, which protect against
strains of the virus responsible for cervical cancer, are recom-
mended for use by the federal Advisory Committee on Immu-
nization Practices for adolescent girls and women in 2006 and
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for adolescent boys and men in 2011 (103). Reported efficacies
from double-blinded studies of up to 100% have been reported for
HPV-16/18 bivalent vaccines against cervical cancers (104, 105).
Among sexually active vaccinated girls ages 14–19, there was an
88% decrease in vaccine-type HPV prevalence in the years follow-
ing the vaccination recommendations in 2006 (103). As a result of
the ACA, HPV vaccination rates can be expected to increase (99)
and a subsequent decline in cervical cancer incidence is predicted
(106). Whether this decline is universally appreciated across racial
and socioeconomic groups will need to be monitored. Cultural
acceptance of this and other recommendations across communi-
ties has been mixed and merits ongoing evaluation. Prioritizing
and addressing identified community concerns will be important
toward achieving the high immunization and reduced cervical
cancer rates across population groups.
Up to 60% of colorectal cancer deaths are estimated to be
avoidable through regular colorectal screening (107, 108). Despite
the proven benefits of colorectal cancer screening, only an esti-
mated 64.5% of adults aged 50–75 years old reported being up
to date with one of the three recommended screening tests (fecal
occult blood testing, sigmoidoscopy, and colonoscopy) in 2008
(100). Though regular screening increased for all racial/ethnic
groups between 2000 and 2008, Hispanic and Black-Americans
have consistently been less likely to be up-to-date with colorectal
cancer screening compared to Whites (109). The ACA’s provision
of increased access to colorectal cancer screening tests through
required health plan coverage and the removal of cost-sharing for
fecal occult blood testing, sigmoidoscopy, and colonoscopy will
likely result in a decrease in these screening disparities (110).
In 2010, 75% of women aged 40 or older reported having a
mammogram within the past 2 years (95). However, after more
than 20 years of increased mammography use, recent recom-
mendation changes delay initiation of routine mammography
screening until age 50 and undergoing mammography at reduced
frequency (17). Higher rates of insurance and removal of cost-
sharing will increase access to mammograms, and recommenda-
tion changes can be expected to better detect true disease. Breast
cancer screening uptake rates with the new mammography guide-
lines will be known in the coming years, but long-term effects due
to increased access to screening and treatment through the ACA
will not be clear for much longer.
Not all of the Americans gaining insurance through the ACA
will utilize preventive services. Utilization rates for recent cancer
screening programs targeting vulnerable low-income populations,
National Breast and Cervical Cancer Early Detection Program and
the Colorectal Cancer Control Program, yielded utilization rates
of 30 and 18%, respectively (111, 112). Although these programs
were small and population characteristics of the newly insured U.S.
population may differ, optimistic predictions on improved cancer
outcomes based on high rates of screening and early disease stage
detection may not be borne out and data on actual utilization of
preventive services across racial and ethnic groups, even without
cost-sharing, will require close monitoring.
Some apparent contradictions in ACA mandates complicate
the potential positive impact of the law’s provisions on cancer care.
Although the ACA mandates insurers to cover a number of preven-
tive services without cost-sharing, it does not require insurers to
cover follow-up testing when abnormalities are detected during
the initial screening examination (113). Coverage for genetic
counseling for women with high risk of having a BRCA gene
mutation is mandated by the ACA, but genetic testing in these
high-risk patients is not necessarily covered (113). This situa-
tion may limit potential improvements in cancer outcomes that
could result from improved screening with fully covered follow-
up care. Another important issue is addressing poorer outcomes
among the patient populations with cancer-related comorbidities.
The American Society of Clinical Oncology, in its statement on
the ACA, noted that “What remains less clear is how these provi-
sions . . .will affect the growing number of individuals who have
already been diagnosed with cancer and are at increased risk for
developing secondary cancers and other diseases . . .” (113).
The ACA provisions related to expanding access to preventive
and early detection services will impact the number and staging
of new cancer diagnoses in the coming years. It is less certain
what the short- and long-term impact of the implementation of
these requirements will be on overall cancer mortality and on
cancer outcomes disparities. Previous health services literature
suggests that the improved access to care and provider coverage
requirements could accelerate the recent trend of declining can-
cer disparities in the U.S. The universality of improved outcomes
across all population groups needs to be assured. Monitoring the
magnitude and racial/ethnic distribution of outcome trends is crit-
ical. Identifying and addressing shortcomings in the legislation as
it pertains to minimizing and eliminating cancer health disparities
must be an ongoing process.
STRENGTHS AND LIMITATIONS
This work describes primarily Black–White differences in cancer
mortality. It is important to acknowledge that data on Black-
Americans cannot be assumed to be representative of other vulner-
able populations. Although some of the most striking differences
in cancer mortality are between Black and non-Hispanic White
populations (114), there are significant disparities that affect His-
panic, Asian, and American-Indian/Alaska-Native diasporas. The
topic of cancer disparities is broad, encompassing all cancer sites,
and other specific sites have larger or smaller racial disparities than
the sites reported here. This review focused on four major cancer
sites with high incidence rates and mortality rates. These cancers;
lung, colorectal, female breast, and prostate cancer, represent an
estimated 50% of incident cancers and 48% of cancer deaths in
the U.S. (114). Therefore, while not inclusive of specifics on all
cancer types, this review highlights similarities and differences in
disparity trends across some significant cancers types in the U.S.
A major strength of this review is the quality of the dataset
used, the National Cancer Institute’s surveillance, epidemiology,
and end results (SEER) dataset. SEER contains cancer incidence
and survival data from population-based cancer registries. Dataset
coverage includes approximately 28 percent of the U.S. population,
including 26% of the African-American population. The represen-
tativeness of the sample and the data quality permit extrapolation
to the U.S. population. Broadening the discussion framework to
explore the potential impacts of ACA mandates on cancer dispar-
ities add breadth to this review’s discussion. The focus on cancer
outcomes rather than incidence permits examination of disparities
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related to post diagnosis treatment access and care and subsequent
outcomes disparities. This avoids assessing longer-term exposures,
accounting for latency periods and is more reflective of disparities
variables relevant to the past decade.
CONCLUSION
Although progress has been made since 2002 Institute of Med-
icine’s report on racial/ethnic disparities, many cancer-related
disparities persist. Smoking prevalence remains higher for Black
men than for White men, for White women than for Black women,
and among individuals of low SES. Public health programs focus-
ing on prevention have not been universally distributed and
received. Uptake of early detection methods remains low for some
racial/ethnic groups. Limited access to and utilization of advanced
cancer therapies persist for a number of populations. The ACA
addresses these issues in a number of ways: through improved
access to care, the requirement of essential benefits, and the PCORI
Advisory Panel on Addressing Disparities. It is premature to pre-
dict with any certainty the impact of ACA on cancer outcomes and
disparities. However, the broad reaching provisions of the law pro-
vide a measure of optimism that the law may contribute to further
declines in racial/ethnic disparities in overall cancer mortality. This
optimism must be tempered with awareness of the law’s limitations
to redress underlying societal inequities. The implementation of
the affordable care act in 2010, with its goals of addressing and
further reducing health disparities, is commendable. However, it
is unlikely that eliminating cancer and other health disparities
can be achieved through health care mandates alone. Redefining
the framework of cancer disparities research beyond health care
is critical. Funding of cancer disparities research, which includes
assessment of the impact of economic, education, and social poli-
cies on health outcomes, will inform and broaden the agenda
toward solutions to eliminate cancer disparities.
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